Orthofix Medical (NASDAQ:OFIX) Major Shareholder Juniper Investment Company, Ll Buys 675,000 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Juniper Investment Company, Ll acquired 675,000 shares of the company’s stock in a transaction on Monday, November 9th. The shares were purchased at an average cost of $7.41 per share, for a total transaction of $5,001,750.00. Following the acquisition, the insider owned 4,446,216 shares of the company’s stock, valued at approximately $32,946,460.56. The trade was a 17.90% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Juniper Investment Company, Ll also recently made the following trade(s):

• On Wednesday, November 11th, Juniper Investment Company, Ll bought 14,803 shares of Orthofix Medical stock. The shares were purchased at an average price of $7.04 per share, for a total transaction of $104,213.12.

Orthofix Medical Stock Down 3.3%

Orthofix Medical stock opened at $6.94 on Friday. Orthofix Medical Inc. has a fifty-two week low of $6.52 and a fifty-two week high of $16.42. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.67 and a current ratio of 3.11. The company has a market capitalization of $282.67 million, a P/E ratio of -6.20 and a beta of 0.66. The stock has a 50-day simple moving average of $9.12 and a 200-day simple moving average of $10.86.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, November 9th. The medical device company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The company had revenue of $207.86 million during the quarter, compared to analysts’ expectations of $210.52 million. Orthofix Medical had a negative return on equity of 10.32% and a negative net margin of 5.39%. Equities research analysts expect that Orthofix Medical Inc. will post -1.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OFIX. Weiss Ratings cut shares of Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. TD Cowen restated a “hold” rating on shares of Orthofix Medical in a research note on Tuesday. Finally, Canaccord Genuity Group dropped their price objective on shares of Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $14.75.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. State of Wyoming raised its stake in shares of Orthofix Medical by 12.2% during the first quarter. State of Wyoming now owns 14,873 shares of the medical device company’s stock worth $171,000 after purchasing an additional 1,617 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Orthofix Medical by 2,434.1% during the third quarter. Parallel Advisors LLC now owns 3,269 shares of the medical device company’s stock worth $31,000 after purchasing an additional 3,140 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Orthofix Medical in the 2nd quarter valued at $30,000. Legal & General Group Plc purchased a new position in Orthofix Medical in the 2nd quarter valued at $37,000. Finally, Vise Technologies Inc. acquired a new position in Orthofix Medical in the 3rd quarter valued at $96,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc. develops and markets medical technologies for spine and orthopedic care. Its products include spinal implants and biologics, bone growth stimulation systems, and solutions used in fracture treatment and limb reconstruction. The company serves hospitals, surgeons, and other health care providers through its Orthofix and SeaSpine businesses. Its offerings span surgical products as well as noninvasive and specialized orthopedic treatments. Orthofix and SeaSpine completed a merger in 2023, combining their spine and orthopedic product portfolios.